EP1137340A4 - Composition et procedes de regulation du poids corporel et des pathologies associees - Google Patents

Composition et procedes de regulation du poids corporel et des pathologies associees

Info

Publication number
EP1137340A4
EP1137340A4 EP99965208A EP99965208A EP1137340A4 EP 1137340 A4 EP1137340 A4 EP 1137340A4 EP 99965208 A EP99965208 A EP 99965208A EP 99965208 A EP99965208 A EP 99965208A EP 1137340 A4 EP1137340 A4 EP 1137340A4
Authority
EP
European Patent Office
Prior art keywords
regulation
composition
body weight
associated conditions
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP99965208A
Other languages
German (de)
English (en)
Other versions
EP1137340A1 (fr
Inventor
Miles B Brennan
Ute Hochgeschwender
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roosevelt Eleanor Institute for Cancer Research Inc
Oklahoma Medical Research Foundation
Original Assignee
Roosevelt Eleanor Institute for Cancer Research Inc
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/374,827 external-priority patent/US6603058B1/en
Application filed by Roosevelt Eleanor Institute for Cancer Research Inc, Oklahoma Medical Research Foundation filed Critical Roosevelt Eleanor Institute for Cancer Research Inc
Publication of EP1137340A1 publication Critical patent/EP1137340A1/fr
Publication of EP1137340A4 publication Critical patent/EP1137340A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99965208A 1998-12-09 1999-12-09 Composition et procedes de regulation du poids corporel et des pathologies associees Ceased EP1137340A4 (fr)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US11158198P 1998-12-09 1998-12-09
US111581P 1998-12-09
US14630699P 1999-07-29 1999-07-29
US14630299P 1999-07-29 1999-07-29
US14630099P 1999-07-29 1999-07-29
US14630599P 1999-07-29 1999-07-29
US14630199P 1999-07-29 1999-07-29
US14630399P 1999-07-29 1999-07-29
US14629999P 1999-07-29 1999-07-29
US14630499P 1999-07-29 1999-07-29
US146301P 1999-07-29
US146303P 1999-07-29
US146306P 1999-07-29
US146299P 1999-07-29
US146304P 1999-07-29
US146300P 1999-07-29
US146305P 1999-07-29
US146302P 1999-07-29
US09/374,827 US6603058B1 (en) 1998-12-09 1999-08-12 Non-human animal model for obesity and uses thereof
PCT/US1999/029337 WO2000033658A1 (fr) 1998-12-09 1999-12-09 Composition et procedes de regulation du poids corporel et des pathologies associees
US374827 2003-02-25

Publications (2)

Publication Number Publication Date
EP1137340A1 EP1137340A1 (fr) 2001-10-04
EP1137340A4 true EP1137340A4 (fr) 2005-12-21

Family

ID=27581011

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99965208A Ceased EP1137340A4 (fr) 1998-12-09 1999-12-09 Composition et procedes de regulation du poids corporel et des pathologies associees

Country Status (6)

Country Link
EP (1) EP1137340A4 (fr)
JP (1) JP2003520015A (fr)
AU (1) AU3117600A (fr)
CA (1) CA2353776A1 (fr)
MX (1) MXPA01005818A (fr)
WO (1) WO2000033658A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064091A2 (fr) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Metallopeptides de melanocortine pour le traitement de dysfonctions sexuelles
AU2001257420A1 (en) * 2000-04-28 2001-11-12 Zengen, Inc. A gene therapy system and method using alpha-MSH and its derivatives
EP1303625A2 (fr) 2000-07-14 2003-04-23 Zycos Inc. Composes en rapport avec alpha-msh et methodes d'utilisation
JP2004510960A (ja) * 2000-09-13 2004-04-08 エレノア　ルーズベルト　インスティテュート 肥満および糖尿病におけるインスリン抵抗性を治療する方法
WO2005000339A2 (fr) * 2003-06-19 2005-01-06 Eli Lilly And Company Agonistes du recepteur 4 de la melanocortine (mc4) et utilisations
EP1644022A1 (fr) * 2003-06-19 2006-04-12 Eli Lilly And Company Utilisation de peptides agonistes du recepteur de la melanocortine-3 (mc3r)
FR2857873B1 (fr) * 2003-07-21 2006-02-24 Courtage Et De Diffusion Codif Procede et produit cosmetique destines a limiter la croissance des tissus adipeux
WO2005102377A1 (fr) * 2004-03-29 2005-11-03 Eli Lilly And Company Utilisations de peptides agonistes du recepteur de la melanocortine 4 (mc4r) administres par perfusion continue
KR101092716B1 (ko) * 2004-04-08 2011-12-09 아스테라스 세이야쿠 가부시키가이샤 화합물 ｗｓ727713
WO2005118573A1 (fr) 2004-05-28 2005-12-15 Smithkline Beecham Corporation Nouveaux composes de diazepine utilises comme ligands des recepteurs 1 et/ou 4 de la melanocortine
US7169773B2 (en) 2004-07-01 2007-01-30 Smithkline Beecham Corporation Compounds
BRPI0518411A2 (pt) * 2004-10-25 2008-11-18 Centocor Inc mimeticorpos que se ligam a receptor de melanocortina, composiÇÕes, mÉtodos e usos
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
WO2006073771A2 (fr) * 2005-01-05 2006-07-13 Eli Lilly And Company Peptides d'agonistes mc4r ou mc3r lies au polyethyleneglycol
US7790671B2 (en) * 2005-10-07 2010-09-07 Codman & Shurtleff, Inc. Implantable pump for protein delivery for obesity control by drug infusion into the brain
WO2009143380A2 (fr) 2008-05-21 2009-11-26 Neurotez, Inc. Procédés de traitement de troubles cognitifs progressifs liés à la dégénérescence neurofibrillaire
WO2010054017A1 (fr) 2008-11-04 2010-05-14 Nikolaos Tezapsidis Compositions à base de leptine et méthodes de traitement de troubles évolutifs de la fonction cognitive provoqués par une accumulation d’enchevêtrements neurofibrillaires et de bêta-amyloïde

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010068A2 (fr) * 1996-09-04 1998-03-12 Oregon Health Sciences University Procedes et reactifs pour deceler et utiliser les agonistes et les antagonistes de recepteur de melanocortine mammalien, visant a modifier le comportement alimentaire chez les animaux

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010068A2 (fr) * 1996-09-04 1998-03-12 Oregon Health Sciences University Procedes et reactifs pour deceler et utiliser les agonistes et les antagonistes de recepteur de melanocortine mammalien, visant a modifier le comportement alimentaire chez les animaux

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"A FRAMESHIFT MUTATION IN HUMAN MC4R IS ASSOCIATED WITH A DOMINANT FORM OF OBESITY", NATURE GENETICS, NEW YORK, NY, US, vol. 20, no. 2, October 1998 (1998-10-01), pages 113 - 114, XP000866527, ISSN: 1061-4036 *
"A FRAMESHIFT MUTATION IN MC4R ASSOCIATED WITH DOMINANTLY INHERITED HUMAN OBESITY", NATURE GENETICS, NEW YORK, NY, US, vol. 20, no. 2, October 1998 (1998-10-01), pages 111 - 112, XP000866528, ISSN: 1061-4036 *
BERTAGNA XAVIER: "Proopiomelanocortin-derived peptides", ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, vol. 23, no. 3, 1994, pages 467 - 485, XP009046900, ISSN: 0889-8529 *
BOSTON BRUCE A ET AL: "Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line", ENDOCRINOLOGY, vol. 137, no. 5, 1996, pages 2043 - 2050, XP002326390, ISSN: 0013-7227 *
CHAGNON YVON C ET AL: "Linkage and association studies between the melanocortin receptors 4 and 5 genes and obesity-related phenotypes in the Quebec Family Study", MOLECULAR MEDICINE (NEW YORK), vol. 3, no. 10, October 1997 (1997-10-01), pages 663 - 673, XP009046979, ISSN: 1076-1551 *
CHEUNG C C ET AL: "PROOPIOMELANOCORTIN NEURONS ARE DIRECT TARGETS FOR LEPTIN IN THE HYPOTHALAMUS", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 138, no. 10, 1997, pages 4489 - 4492, XP009027762, ISSN: 0013-7227 *
FAN W ET AL: "ROLE OF MELANOCORTINERGIC NEURONS IN FEEDING AND THE AGOUTI OBESITY SYNDROME", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 385, 9 January 1997 (1997-01-09), pages 165 - 168, XP002072475, ISSN: 0028-0836 *
HUSZAR D ET AL: "TARGETED DISRUPTION OF THE MELANOCORTIN-4 RECEPTOR RESULTS IN OBESITY IN MICE", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 88, no. 1, 10 January 1997 (1997-01-10), pages 131 - 141, XP000877328, ISSN: 0092-8674 *
JACKSON R S ET AL: "Proopiomelanocortin products and human early-onset obesity.", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. FEB 1999, vol. 84, no. 2, February 1999 (1999-02-01), pages 819 - 820, XP002326389, ISSN: 0021-972X *
MIZUNO T M ET AL: "HYPOTHALAMIC PRO-OPIOMELANOCORTIN MRNA IS REDUCED BY FASTING IN OB/OB AND DB/DB MICE, BUT IS STIMULATED BY LEPTIN", DIABETES, NEW YORK, NY, US, vol. 47, no. 2, February 1998 (1998-02-01), pages 294 - 297, XP001063909, ISSN: 0012-1797 *
POGGIOLI R ET AL: "ACTH-(1-24) and alpha-MSH antagonize feeding behaviour stimulated by kappa opiate antagonists", PEPTIDES, ELSEVIER, AMSTERDAM, US, vol. 7, no. 5, 1986, pages 843 - 848, XP009018115, ISSN: 0196-9781 *
See also references of WO0033658A1 *

Also Published As

Publication number Publication date
MXPA01005818A (es) 2003-07-21
CA2353776A1 (fr) 2000-06-15
AU3117600A (en) 2000-06-26
EP1137340A1 (fr) 2001-10-04
JP2003520015A (ja) 2003-07-02
WO2000033658A1 (fr) 2000-06-15

Similar Documents

Publication Publication Date Title
EP1137340A4 (fr) Composition et procedes de regulation du poids corporel et des pathologies associees
ZA9711421B (en) Method and compositions for weight control
ZA989875B (en) Composition and method for inhibiting the growth of microorganisms including stabilized sodium hypbromite and isothiazolones
PL336326A1 (en) Method of and composition for treating sleep apnoea
EP1143987A4 (fr) Composition naturelle et methode destinees au traitement de dysfonctions sexuelles
EP1027045A4 (fr) Procedes et compositions pour reguler l'activite de la 5-alpha-reductase
EP0918787A4 (fr) Compositions et procedes pour l'inhibition antisens de la traduction de proteines
PL337531A1 (en) Compositions for and methods of inhibiting photo-ageing of skin
PL352014A1 (en) Dietetic of pharmacological composition for preventing or treating hyperoxaluria
GB9422571D0 (en) Haemorrihoidal compositions and method of use
PL336466A1 (en) Composition for and method of fighting against harmful bio-organisms
PL335168A1 (en) Compositions for and methods of reducing intracocular hypertension
HU9802721D0 (en) Method and composition for the treatment and prevention of hyperuricemia
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
AU7755398A (en) Method for reducing body weight
ZA964562B (en) Antipsychotic agents compositions and method of use
GB9814733D0 (en) Method of reducing or preventing malodour
GB9927191D0 (en) Methods and means for regulation of gene expression
EP0997450A4 (fr) PROCEDE DE REDUCTION DE NO x
EP0915706A4 (fr) Procedes de selection pour des composes utiles dans la regulation du poids corporel
IL120128A0 (en) Compositions for the treatment of androgenetic alopecia and hirsutism
HUP9801629A3 (en) Methods and compositions for regulation of cd28 expression
GB9814732D0 (en) Method of reducing or preventing malodour
GB9807019D0 (en) Mastic composition and method of preparing same
EP1096927A4 (fr) Composition pour le traitement du stress

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010704

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 43/00 B

Ipc: 7A 61P 25/00 B

Ipc: 7A 61P 3/04 B

Ipc: 7A 61K 38/03 B

Ipc: 7A 01K 67/027 B

Ipc: 7G 01N 33/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20051107

17Q First examination report despatched

Effective date: 20070403

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20110718